Wells Fargo Bullish on Cepheid, Less so on Qiagen and Quidel, as it Initiates Coverage | GenomeWeb

NEW YORK (GenomeWeb) – Wells Fargo Securities today initiated coverage of Cepheid with an Outperform rating, Qiagen with a Market Perform rating, and Quidel also with a Market Perform rating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.